MedTrace Logo

The Clinical Trial of ADR-001 for IgA Nephropathy

NCT04342325 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-05-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001 for IgA Nephropathy patients.

Conditions

  • Glomerulonephritis , IGA

Interventions

BIOLOGICAL

infusion of ADR-001 (Mesenchymal stem cell)

Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells.

Sponsors & Collaborators

  • Rohto Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Nagoya University

    lead OTHER

Principal Investigators

  • Shoichi Maruyama, MD, PhD · Nagoya University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2022-11-01
Completion
2023-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04342325 on ClinicalTrials.gov